ClinicalTrials.gg
Not yet recruitingNCT07711938Updated Jul 17, 2026

Growth And Safety Outcomes In Infants With Cow´s Milk Protein Allergy (CMPA) Fed A Novel Extensively Hydrolyzed Formula (eHF)

An interventional study of New generation eHF and Commercial eHF in Cow Milk Protein Allergy, sponsored by Société des Produits Nestlé (SPN). Not yet recruiting. Open to participants aged 29 Days to 22 Weeks. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Société des Produits Nestlé (SPN) (part of Nestlé S.A.) · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
29 Days to 22 Weeks
Sex
All
01

Study summary

Growth and safety Outcomes in infants with CMPA fed a novel extensively hydrolyzed formula.

02

Conditions studied

  • Cow Milk Protein Allergy
03

In context

Lead sponsor

Société des Produits Nestlé (SPN) is the lead sponsor of 324 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
29 Days to 22 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Full-term infant(gestational age ≥37 weeks and ≤42 weeks).
  2. Birth weight ≥2500 g and ≤4500 g.
  3. Parent(s)/LAR deemed able to provide written for participation of their infant in the study (in the opinion of the investigator).
  4. Participant aged ≥29 days (>4 weeks) and \<5 months (≤22 weeks) at time of enrollment.
  5. Not breastfed at time of Screening Visit.
  6. History of an immediate-type (IgE-mediated) allergic reaction to a cow's milk-containing food or at least 2 persistent severe symptoms suggestive of delayed-onset (non-IgE-mediated) CMPA.

Exclusion criteria

Exclusion Criteria:

  1. Prior use of eHF, HRF or AAF for more than 2 weeks before randomization.
  2. Congenital illness or malformation that may affect growth, or significant pre-natal and/or serious post-natal disease other than CMPA before randomization (per investigator's medical decision).
  3. Demonstrated chronic malabsorption not due to CMPA.
  4. History of severe anaphylaxis to CMP.
  5. Infants whose parent(s)/LAR cannot be expected to comply with study procedures.
  6. Currently participating or having participated in another clinical study since birth.
  7. Infants with a history of confirmed food protein induced enterocolitis syndrome due to other foods than CMP or Heiner syndrome.
  8. Infants with history of oral immunotherapy for CMPA.
  9. Diagnosed eosinophilic esophagitis.
  10. Received systemic oral or injected for more than 3 days (72 hours) within 2 weeks prior to the Screening Visit (topical corticosteroids allowed).
  11. Received systemic antibiotics within 1 week prior to Screening Visit (topical antibiotics, e.g., mupirocin allowed).
  12. Infants who are currently receiving treatment with immunomodulators (immunoglobulins, allergen extracts, or similar) or immuno-suppressants (azathioprine, cyclosporine or similar) within 2 weeks of Screening Visit (topical cyclosporine, tacrolimus, pimecrolimus or similar topical eczema treatments allowed), as well as infants with immune disorders which can compromise the immune function.
  13. Infants with a past or current disease or disorder which, in the opinion of the investigator or the sponsor either places the participant at risk because of participating in the study or may influence the results of the study, or the participant's ability to participate in the study (e.g., cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine or metabolic disorders, , major physical impairment, immunodeficiency, infectious disease or abnormal laboratory results as per the investigator's judgment).
  14. Parent(s)/LAR being in any relationship or dependency with the sponsor, and/or the investigator, and/or study staff.
  15. Underage parents (under 18 years old).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    Test Formula

    New generation eHF

    Dietary Supplement: New generation eHF

  • Active comparator
    Control Formula

    Commercial eHF

    Dietary Supplement: Commercial eHF

Interventions

  • Dietary supplementNew generation eHF

    New generation of a whey-based eHF formula intended for the dietary management of infants with CMPA.

  • Dietary supplementCommercial eHF

    Commercial whey-based eHF formula intended for the dietary management of infants with CMPA.

06

What researchers measure

Primary outcomes

  1. Weight Gain Over 16 Weeks

    To demonstrate non-inferiority in growth in infants fed with the Test formula, compared to infants fed with the Control formula over the first 16 weeks of formula intake.

    Time frame: 16 weeks

Secondary outcomes

  1. Incidence of Adverse Events of Special Interest (AESIs)

    To evaluate the safety and tolerability of the Test formula, including effects on "adverse events of special interest (AESIs)", which include lower respiratory tract infections (LRTIs), upper respiratory tract infections (URTIs), ear infections/otitis media, gastrointestinal infections and other viral or bacterial infections including urinary tract infections (UTIs).

    Time frame: 52 weeks

  2. Growth Parameters: Weight

    The growth by body weight (in g) of infants over 52 weeks.

    Time frame: 52 weeks

  3. Growth Parameters: Length

    The growth by body length (in cm) of infants over 52 weeks

    Time frame: 52 weeks

  4. Quality of Life Scores (ITQOL)

    Quality of life over 52-weeks assessed by validated Quality of Life (QoL) scale: Infant and Toddler Quality of Life \[ITQOL\] Minimum score: 0 Maximum score: 100 Interpretation: Higher scores indicate better health-related quality of life, better functioning, or less negative impact on the child/family (depending on the specific domain). A score of 0 represents the worst health/status, while 100 represents the best health/status

    Time frame: 52 weeks

  5. Stool Frequency and Stool Characteristics (BITSS)

    Stool frequency and characteristics over 52 weeks based on Brussels Infant and Toddler Stool Scale (BITSS). Scale categories: 7 stool photographs corresponding to stool consistency types BITSS photographs are often grouped into: Hard: Types 1-3 Formed: Type 4 Loose: Types 5-6 Watery: Type 7 Interpretation: Lower categories (1-3): harder stools, potentially associated with constipation. Middle category (4): formed/normal stool consistency. Higher categories (5-7): increasingly loose to watery stools, potentially associated with diarrhea.

    Time frame: 52 weeks

  6. Resolution of CMPA-Related Symptoms

    Rate of adequate clinical response and time to symptom resolution of CMPA-related symptoms (in days) collected on patient-reported outcome tool (PRO) based on parent(s)/legally authorized representative(s) (LAR) report.

    Time frame: 52 weeks

  7. Formula intake compliance

    Formula intake (in ml) compliance (number of feeds per day) based on parent(s)/LAR report records collected via electronic data capture (EDC)/interactive response technology (IRT).

    Time frame: 52 weeks

  8. Healthcare resources utilization

    Healthcare Resources Utilization (HCRU) over the 52-week intervention period, based on parent(s)/LAR report and medical records (such as: number of hospitalizations, number of unscheduled emergency department attendances, general practitioner/pediatrician visits)

    Time frame: 52 weeks

  9. Growth Parameters: Head Circumference

    The growth by head circumference (in cm) of infants over 52 weeks

    Time frame: 52 weeks

  10. Quality of Life Scores (FLIP)

    Quality of life over 52-weeks assessed by validated QoL scale: Food hypersensitivity family Impact \[FLIP\] Lower categories (1-3): harder stools, potentially associated with constipation. Middle category (4): formed/normal stool consistency. Higher categories (5-7): increasingly loose to watery stools, potentially associated with diarrhea.

    Time frame: 52 weeks

  11. Resolution of Cow Milk Protein Allergy (CMPA)-Related Symptoms

    Rate of adequate clinical response and time to symptom resolution of CMPA-related symptoms (in days) collected on Scoring Atopic Dermatitis Eczema Score (SCORAD) Minimum score: 0 Maximum score: 103 Interpretation: Higher scores indicate more severe eczema and therefore a worse outcome. Lower scores indicate less severe disease and a better outcome

    Time frame: 52 weeks

  12. Resolution of CMPA-Related Symptoms

    Rate of adequate clinical response and time to symptom resolution of CMPA-related symptoms (in days) collected on Infant Gastrointestinal Symptom Questionnaire (IGSQ) Minimum score: 13 Maximum score: 65 Interpretation: Higher scores indicate more gastrointestinal symptoms and poorer feeding tolerance (worse outcome). Lower scores indicate fewer GI symptoms and better tolerance.

    Time frame: 52 weeks

  13. Resolution of CMPA-Related Symptoms

    Rate of adequate clinical response and time to symptom resolution of CMPA-related symptoms (in days) collected on Cow's Milk-Related Symptom Score (CoMiSS). Minimum score: 0 Maximum score: 33 Interpretation: Higher scores indicate more severe cow's milk-related symptoms and therefore a worse outcome. Lower scores indicate fewer symptoms and a better outcome.

    Time frame: 52 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Jul 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 17, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
May 30, 2029
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07711938
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jul 31, 2028 (estimated)
Completion
May 30, 2029 (estimated)
Last update
Jul 17, 2026

Study contacts

Kamila Laskowska
Contact
kamila.laskowska@rd.nestle.com
41 21 785 87 32
Giulia Ingrassia
Contact
giuliamarialaura.ingrassia@rd.nestle.com
+41 21 785 92 23

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion